| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,000 | 0,000 | 10.04. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FIBROBIOLOGICS Aktie jetzt für 0€ handeln | |||||
| Fr | FibroBiologics presents preclinical data on thymic organoids | 2 | Investing.com | ||
| Fr | FibroBiologics, Inc.: FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity | 1 | GlobeNewswire (USA) | ||
| Do | FibroBiologics optimiert Kosten: Untermietvertrag vorzeitig beendet, Firmensitz verlegt | 1 | Investing.com Deutsch | ||
| 03.04. | FibroBiologics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.04. | FibroBiologics closes $3M public offering with warrants | 2 | Investing.com | ||
| 02.04. | FibroBiologics, Inc.: FibroBiologics Announces Closing of $3 Million Public Offering | 3 | GlobeNewswire (USA) | ||
| 01.04. | FibroBiologics prices $3M public offering at $1.32/share | 1 | Investing.com | ||
| 01.04. | FibroBiologics, Inc.: FibroBiologics Announces Pricing of $3 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 31.03. | FibroBiologics completes first CYWC628 batch for clinical trials | 2 | Investing.com | ||
| 31.03. | FibroBiologics, Inc.: FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial | 457 | GlobeNewswire (Europe) | HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the... ► Artikel lesen | |
| 31.03. | EXCLUSIVE: FibroBiologics Moves Forward With Human Trial For Diabetic Foot Ulcer Therapy | 6 | Benzinga.com | ||
| 30.03. | FibroBiologics prices combined unit offering at $4.40 and 1-for-20 reverse split to regain Nasdaq compliance | 4 | Seeking Alpha | ||
| 30.03. | XFRA SG00: AUSSETZUNG/SUSPENSION | 130 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFIBROBIOLOG. O.N.... ► Artikel lesen | |
| 30.03. | XFRA NEW INSTRUMENTS AVAILABLE ON 30.03.2026 | 217 | Xetra Newsboard | The following instruments on XETRA do have their first trading 30.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 30.03.2026
Aktien
1 SE0008091573 Bonava AB AB
2 SE0007184189... ► Artikel lesen | |
| 27.03. | FibroBiologics, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 27.03. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.03.2026 | 723 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.03.2026.ISIN NameCA98420Q3061 XORTX... ► Artikel lesen | |
| 27.03. | XFRA ISIN CHANGE | 458 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA98420Q3061 XORTX Therapeutics Inc. 27.03.2026 CA98420Q4051 XORTX Therapeutics Inc. 30.03.2026 Tausch 5:1GB0009296665 Videndum... ► Artikel lesen | |
| 26.03. | D. Boral Capital downgrades FibroBiologics stock rating to hold | 6 | Investing.com | ||
| 25.03. | FibroBiologics announces 1-for-20 reverse stock split | 1 | Investing.com | ||
| 25.03. | Stocks to watch after market on Wednesday: DRVN, EGO, FBLG | 3 | Seeking Alpha |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,30 | +0,06 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Biontech mit einem Kursziel von 155 US-Dollar auf "Buy" belassen. Die Produktpipeline des Antikörperspezialisten stehe wieder... ► Artikel lesen | |
| MODERNA | 43,000 | -0,23 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,078 | +23,81 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| NOVAVAX | 6,910 | +0,29 % | Activist investor revives campaign to overhaul Novavax board | ||
| NANOREPRO | 1,415 | 0,00 % | NanoRepro-Aktie: Eine neue Ära beginnt | Die NanoRepro-Aktie befindet sich seit dem Hoch im August letzten Jahres mit 2 € in einem langfristigen Abwärtstrend. Am Dienstag gewinnt sie aktuell +4% und steht bei rund 1,45 €. Das Lifestyle-Unternehmen... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,886 | -4,83 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| INFLARX | 0,910 | -0,49 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,340 | +3,98 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Warrant Terms Amendment | Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,980 | -0,32 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| ABIVAX | 103,70 | -0,38 % | EQS-News: ABIVAX: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01.04.2026 / 22:05 CET/CEST
The... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,181 | -4,57 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| IBIO | 1,841 | -1,39 % | iBio, Inc.: iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia | IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN... ► Artikel lesen |